Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Not sure if already posted but more coverage in France.
https://www.cliniquemutualisteamberieu.fr/linterferon-beta-1a-sng001-nebulise-inhale-aide-les-patients-atteints-de-covid-19-a-recuperer
The last paragraph, courtesy of google translate, “ The study highlights the need for an effective and well-tolerated drug to reduce mortality from COVID-19. So far, the virus has infected more than 54 million people around the world, with more than 1.31 million deaths”.
The site translates to “medical information by health professionals”.
Coverage is certainly picking up.
Shrek
Hello all, nice coverage in this article.
https://www.news-medical.net/news/20201115/Inhaled-nebulized-interferon-beta-1a-(SNG001)-helps-COVID-19-patients-recovers.aspx
Shrek
Hello another search hit from an Indian based news site.
https://hindikhabre.com/covid-19-analysis-inhaled-a-number-of-sclerosis-drug-speeds-restoration/
According to google, Hindi Khabar is an Indian 24-hour Hindi news channel.
Enjoyed the discussion this morning, thanks all.
Shrek
Good morning all, this article has turned up in my search today. Positive coverage which will do no harm.
https://www.thehindubusinessline.com/news/science/immune-system-protein-inhalation-could-alleviate-covid-19-severity-study/article33100161.ece
Morning all. Not sure if this has been posted.
https://www.nature.com/articles/s41422-020-00435-z
I have read it and my understanding is it’s more supporting scientific evidence why interferon is effective.
“Indeed, clinical observation has found that critically ill patients with normal PCO2 can be rescued, while it is very difficult to rescue patients with altered PCO2.31 Therefore, targeting IFN-triggered AhR pathway might be a potential strategy to effectively treat COVID-19 patients.”
Cheers
Shrek
Morning all, nice mention in the article.
https://www.evaluate.com/vantage/articles/analysis/spotlight/scanning-horizon-future-covid-19-treatments
https://www.sciencedaily.com/releases/2020/10/201030122532.htm
Prof Tom has been busy. I know he is talking about COPD but I liked the digital aspect of “having an expert in your pocket “
Professor Tom Wilkinson of the University of Southampton who developed the app and led the trial said, "COPD has a significant impact on peoples' daily lives so we wanted to develop a means of healthcare that is like having an expert in your pocket; giving you advice whenever you need it.
"The transition towards digital healthcare has been taking place for some time but has accelerated since the outbreak of COVID-19. Patients with conditions such as COPD can be particularly vulnerable now so it is important that we have evidence of the effectiveness of these technologies.
"Hopefully the success of this will lead to further use and the development of similar products that allow patients to manage other conditions to further improve their wellbeing and reduce the burden on the NHS."
Hello all, just found this article from the telegraph.
https://apple.news/AZur9Ivc-T6m1eu7LYvasKg
Donald Trump is taking an antibody ****tail set to be rolled out to coronavirus patients in 40 hospitals in the UK next week.
The US President, who has tested positive for Covid-19 along with the First Lady, was taken to Walter Reed military hospital in Maryland late on Friday as a precaution after experiencing mild symptoms, including fatigue.
Mr Trump is being given the anti-viral drug Remdesivir, as well as an antibody treatment which is part of pioneering trials in the UK and has shown promising results.
The ****tail, called REGN-COV2, is made by the pharmaceutical company Regeneron, which previously developed a similar antibody drug against Ebola.
Peter Horby, professor of emerging infectious diseases at Oxford University and co-chief investigator of the RECOVERY trial, which is now testing the ****tail, said it going to be made available to dozens of UK hospitals.
"We have it in the RECOVERY trial in the UK - we started that over last weekend. It's currently available in about three hospitals in the North. We'll be rolling it out next week to another 30 or 40 hospitals," he told BBC Radio 4's Today programme.
"It's antiviral so will work in patients in which the virus is still replicating, but could be used at any stage of the disease and for any age group.
"It's an artificial antibody and a ****tail of two antibodies. It's designed so it binds strongly to a protein on the surface of the virus. It helps prevent the virus from attaching to the cells, entering the cells and replicating. It also helps our own immune system to attack and kill the virus.
"The class of drugs, these artificial antibodies, have been around for quite a while now and are extensively used in inflammatory conditions and cancers. They're pretty safe and well understood. This particular drug has probably been given to 400 or 500 mild or severe patients in different trials and so far there's be no worrying safety signals.
"It's very promising, it's very potent. In the laboratory in cell cultures it has a very strong effect against the virus and there have been some studies of artificially infected animals in which it showed benefit. Of the drugs available, it's one of the most promising."
Professor Horby said the response to vaccines can be poorer as you get older, but this class of drugs have a long life so one treatment can provide protection for a month or six weeks - making them "attractive for the older population".
Remdesivir, which Mr Trump is taking alongside the antibody ****tail, was the first drug approved to treat Covid-19 in the UK.
The antiviral was developed by biopharmaceutical company Gilead Sciences to tackle Ebola and is administered intravenously. It works by disrupting the virus's replication process.
Matt Han****, the Health Secretary, described it as “probably the biggest step forward in the treatment of coronavirus since the crisis b
Hello all, has this been posted? It’s dated 24th September and it turned up as I was searching on Prof Wilkinson.
http://www.isrctn.com/ISRCTN57085639
Good morning all, this has turned up in my daily search. Apologies If already posted. It’s dated today.
https://www.hindustantimes.com/india-news/genetic-defects-may-affect-ability-to-fight-covid/story-WzJfpOXHEZzY3Al8K6B3AJ.html
Shrek
https://www.cell.com/cell-reports/fulltext/S2211-1247(20)31174-8
I’m not sure if this has already been posted, if it has apologies. I found it hard going as my background is not science, however it was worth reading . If it hasn’t been posted I would be grateful of the opinions of those with a better grasp of science. I took it as positive and made sense as to why our treatment is so effective.
“ Thus, our data demonstrate that SARS-CoV-2 ORF3b is a potent inhibitor of human IFN-I activation, even though it only comprises 22 amino acids.”
Article in LeNouvelliste today. Nothing new reported but positive coverage. It is a Swiss French language daily from what I can see.
https://www.lesoleil.com/actualite/monde/un-medicament-reduirait-de-79--le-risque-de-developper-une-forme-severe-du-coronavirus-b689c5c936585fd2c21dc86024d1a731
https://www.medscape.com/viewarticle/937411
Video posted yesterday and approximately 09:29 mention of inhaled interferon. I found the rest of the video useful.
Hello all. I have enjoyed reading this board for the last couple of months and am grateful to those who have posted some great articles and helped my research.
I have finally got round to joining so I can use the filter as the good posts are sadly getting drowned out.